Clinical experiences with a new  -sympathicomimetic substance in the provoked attack in occupational asthma.
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects; D002986:Clinical Trials as Topic; D004781:Environmental Exposure; D005433:Flour / Q000009:adverse effects*; D006801:Humans; D008168:Lung / Q000187:drug effects; D008297:Male; D009921:Metaproterenol / Q000494:pharmacology*; D009784:Occupational Diseases / Q000188:drug therapy*; D010636:Phenols / Q000494:pharmacology; D010919:Placebos; D010993:Plethysmography, Whole Body; D011674:Pulse / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D000336:Aerosols; D010636:Phenols; D010919:Placebos; D009921:Metaproterenol